RSS Feeds
Immunomodulators in Clinical Medicine
- ANTHONY S. FAUCI, M.D.;
- STEVEN A. ROSENBERG, M.D., Ph.D.;
- STEPHEN A. SHERWIN, M.D.;
- CHARLES A. DINARELLO, M.D.;
- DAN L. LONGO, M.D.; and
- H. CLIFFORD LANE, M.D.
Abstract
A major difficulty limiting the use of immunomodulators in clinical medicine has been the complexity of the immunoregulatory network in which modulation of one component usually perturbs the entire system, thus diminishing the specificity of the approach. Lymphokineactivated killer cells infused with interleukin-2 have proved effective in inducing remissions in several advanced cancers, particularly metastatic renal cell carcinomas. The interferons have shown direct antiproliferative effects as well as specific effects on immune function. Alpha-interferon has shown impressive antitumor effects in hairy cell leukemia and significant antiviral effects in papillomavirus infection of the genital tract. Interleukin-2 has multifaceted effects on various limbs of the inflammatory and immune responses and may be the critical common denominator in the adjuvant effects of several other compounds. Monoclonal antibodies have assumed an increasing role in diagnostic and therapeutic approaches to neoplastic and immunemediated diseases. Finally, several immunomodulators are currently being tested in the treatment of the immune defect of the acquired immunodeficiency syndrome.
- acquired immunodeficiency syndrome
- B lymphocytes
- cancer immunotherapy
- chronic myelogenous leukemia
- hairy cell leukemia
- immunologic adjuvants
- immunomodulators
- interferons
- interleukin-1
- interleukin-2
- Kaposi sarcoma
- kidney neoplasms
- lymphokine-activated killer cells
- lymphokines
- monoclonal antibodies
- myelocytic leukemia
- natural killer cells
- neoplasm metastases
- non-Hodgkin lymphoma
- T-cell lymphoma
- thymus hormones
- T lymphocytes
- transfer factor
Article and Author Information
-
▸An edited transcription of a Combined Clinical Staff Conference held 11 June 1986 at the Clinical Center, Bethesda, Maryland, and sponsored by the National Institutes of Health, U.S. Department of Health and Human Services.
-
▸Authors who wish to cite a section of the conference and specifically cite its author can use this example for the form of reference:
SHERWIN SA. The interferons, pp 425-6. In: FAUCI AS, moderator. Immunomodulators in clinical medicine. Ann Intern Med. 1987;106:421-33.
-
▸Requests for reprints should be addressed to Dr. Anthony S. Fauci; National Institutes of Health, Building 10, Room 11B-13; Bethesda, MD 20892.
